These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21441781)

  • 1. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age.
    Gajdos V; Soubeyrand B; Vidor E; Richard P; Boyer J; Sadorge C; Fiquet A
    Hum Vaccin; 2011 May; 7(5):549-56. PubMed ID: 21441781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
    Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
    Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a trivalent tetanus, low dose diphtheria, inactivated poliomyelitis booster compared with a standard tetanus, low dose diphtheria booster at six to nine years of age. Munich Vaccine Study Group.
    Stojanov S; Liese JG; Bendjenana H; Harzer E; Barrand M; Jow S; Dupuy M; Belohradsky BH
    Pediatr Infect Dis J; 2000 Jun; 19(6):516-21. PubMed ID: 10877165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined vaccine against tetanus, diphtheria and polio. A randomized controlled study of immunogenicity and tolerance].
    Banzhoff A; Donner-Banzhoff N; Schwenke C; Girgsdies OE; Jilg W
    Fortschr Med Orig; 2001 Jan; 118(4):169-72. PubMed ID: 11217682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV).
    Laroche P; Barrand M; Wood SC; Van Hasbrouck K; Lang J; Harzer E; Hessel L
    Infection; 1999; 27(1):49-56. PubMed ID: 10206791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
    Bégué PC; Grimprel EM; Giovannangeli MD; Abitbol VI
    Pediatr Infect Dis J; 1998 Sep; 17(9):804-9. PubMed ID: 9779766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
    Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
    Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
    Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
    Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
    Dominicus R; Galtier F; Richard P; Baudin M
    Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
    Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children.
    Collins CL; Salt P; McCarthy N; Chantler T; Lane L; Hemme F; Diggle L; Buttery J; Kitchin NR; Moxon ER; Pollard AJ
    Vaccine; 2004 Oct; 22(31-32):4262-9. PubMed ID: 15474717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines.
    Mark A; Björkstén B; Granström M
    Vaccine; 1995 May; 13(7):669-73. PubMed ID: 7668036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
    Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
    Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
    Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
    Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.